News & Updates

Show Multimedia Only

Long-term risankizumab safe, effective in moderate-to-severe plaque psoriasis

20 Dec 2023 by

Treatment with risankizumab in the long term shows lasting efficacy against moderate-to-severe plaque psoriasis and has good tolerability, according to the LIMMitless study.

20 Dec 2023

Add-on ribociclib continues to triumph in early breast cancer

20 Dec 2023 by

Coming on the heels of the second interim analysis, the protocol-specified final invasive disease-free survival (iDFS) analysis of the phase III NATALEE trial continues to show a highly significant iDFS benefit with the combination of the CDK 4/6 inhibitor ribociclib and a nonsteroidal aromatase inhibitor (NSAI) in individuals with HR+/HER2- early breast cancer.

20 Dec 2023

Cilostazol safe but not neuroprotective

20 Dec 2023

In the treatment of people with mild cognitive impairment, cilostazol is well tolerated but falls short of preventing further cognitive decline, according to the results of the phase II COMCID* trial.

20 Dec 2023

Most HF patients do not undergo loop diuretic dose reduction after SGLT2i initiation

19 Dec 2023

Majority of the patients with heart failure (HF) who have initiated treatment with sodium-glucose cotransporter 2 inhibitor (SGLT2i) show no change in loop diuretic dose, reports a study.

19 Dec 2023

Antipsychotic use for amphetamine-induced psychosis tied to longer hospital stay

19 Dec 2023

Patients with amphetamine-induced psychosis (AIP) who have been treated with antipsychotics appear to have a longer length of stay (LOS) than those who did not receive such treatment, reports a study.

19 Dec 2023

Real-world data highlight tofacitinib potential for irAE management in cancer patients

19 Dec 2023 by

In a study presented at ESMO Asia 2023, tofacitinib, a rapidly acting JAK-STAT inhibitor with reported efficacy in the treatment of various autoimmune diseases, was effective for the management of difficult-to-treat immune-related adverse events (irAEs) and was well-tolerated in cancer patients, with only a few patients developing infectious events.

19 Dec 2023

Add-on PCSK9 inhibitor cuts LDL-C by half, allows infrequent dosing in patients maxed out on statins

19 Dec 2023 by

Injection with the novel, long-acting PCSK9 inhibitor recaticimab once every 3 months reduces LDL-cholesterol (LDL-C) levels by >50 percent compared with placebo in patients already maxed out on statins in the phase III REMAIN-2 trial.

19 Dec 2023

Real-world data favour etelcalcetide for treating SHPT in multiethnic Asians

18 Dec 2023 by

Etelcalcetide proves beneficial in the real-world treatment of secondary hyperparathyroidism (SHPT) in multiethnic Asian haemodialysis patients, with the added advantage of reducing pill burden, as shown in a study from Singapore.

18 Dec 2023